Psychedelic-assisted therapy offers hope, but faces FDA hurdles
https://flip.it/WwP55k #psychedelic #ketamine #psilocybin — research involving head-to-head double-blinded comparisons of
#ketamine and
#psilicybin in development!
#neuroscience #psychedelicmentalhealth #fda
Psychedelic-assisted therapy offers hope, but faces FDA hurdles
Advocates are pushing for approval of psychedelic-assisted therapy from the FDA, seeking a means of therapy without fear of breaking laws. At the same time, University of Iowa researchers are testing how psychedelic-assisted therapy could be used to treat alcoholism.
https://www.cnbc.com/2021/11/29/peter-thiel-backed-atai-snaps-up-compass-pathways-shares.html Pepperidge Farms remembers— 2021: Peter Thiel-backed psychedelic start-up (atai life sciences) increases stake in Compass Pathways
#fda #psychedelics #psychedelic Fascism’s finest are patenting forms of generic medicines & molecules —
#ketamine #psilicybin #dmt #mescaline #mdma are off-patent, and do we really need venture-capitalist funded designer drugs sold to us by fascism? The narrative of “Wild West of ketamine clinics ” vs try Spravato by Johnson & Johnson - tired
Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways
Atai Life Sciences, the Peter Thiel-backed psychedelic start-up, has increased its stake in Compass Pathways.
UNM physician trying psychedelic drugs to help people combat PTSD, depression
Psychedelic assisted therapy is making its way to New Mexico, and Dr. Larry Leeman is at the forefront of the studies.
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement...
Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats - Translational Psychiatry
Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin’s general mode of action and (2) AUD-specific alterations of responsivity to psilocybin treatment in the brain that are crucial for treatment development. Here, we conducted a randomized, placebo-controlled crossover pharmaco-fMRI study on psilocybin effects using a translational approach with healthy rats and a rat model of alcohol relapse. Psilocybin effects were quantified with resting-state functional connectivity using data-driven whole-brain global brain connectivity, network-based statistics, graph theory, hypothesis-driven Default Mode Network (DMN)-specific connectivity, and entropy analyses. Results demonstrate that psilocybin induced an acute wide-spread decrease in different functional connectivity domains together with a distinct increase of connectivity between serotonergic core regions and cortical areas. We could further provide translational evidence for psilocybin-induced DMN hypoconnectivity reported in humans. Psilocybin showed an AUD-specific blunting of DMN hypoconnectivity, which strongly correlated to the alcohol relapse intensity and was mainly driven by medial prefrontal regions. In conclusion, our results provide translational validity for acute psilocybin-induced neural effects in the rodent brain. Furthermore, alcohol relapse severity was negatively correlated with neural responsivity to psilocybin treatment. Our data suggest that a clinical standard dose of psilocybin may not be sufficient to treat severe AUD cases; a finding that should be considered for future clinical trials.
Advocates File California Ballot Initiative To Legalize Psychedelics For Medical, Therapeutic And Spiritual Use In 2024
Advocates in California filed a ballot initiative with state officials on Friday that would create a right “to obtain and use psychedelics for medical, therapeutic and spiritual purposes” with the recommendation of a doctor. It would also allow adults to possess and use the substances in their home as well as cultivate entheogenic plants and […]
https://www.frontiersin.org/articles/10.3389/fpsyt.2022.917199 2022 meta-analysis suggests the
#psychedelic experience is important to the outcome in medicines including
#ketamine #mdma #lsd #psilicybin #ayahausca and
#mescaline Preparation, support and integration of that experience, regardless of the medicine, minimizes risk and harm and maximizes mental health outcomes.
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both symptom reduction and improved quality of life. In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were analyzed for association between mystical experience and symptom reduction, in areas as diverse as cancer-related distress, substance use disorder, and depressive disorders to include treatment-resistant. Ten of the twelve established a significant association of correlation, mediation, and/or prediction. A majority of the studies are limited, however, by their small sample size and lack of diversity (gender, ethnic, racial, educational, and socioeconomic), common in this newly re-emerging field. Further, 6 out of 12 studies were open-label in design and therefore susceptible to bias. Future studies of this nature should consider a larger sample size with greater diversity and thus representation by use of randomized design. More in-depth exploration into the nature of mystical experience is needed, including predictors of intensity, in order to maximize its positive effects on treatment outcome benefits and minimize concomitant anxiety.Systematic Review Registration: PROSPERO, identifier CRD42021261752.
PlanetMedicines